## **Medicines Optimisation Committee minutes** 12th May 2022

Present:

Louise Brown, Professional Manager Pharmacy Services, Acute and Regional

Karen Devenney, Senior Manager, Nursing, Quality and Patient Safety

Eimear McCusker (Co-chair), Head of Pharmacy and Medicines Management

Clare McMahon, Head of Resource Utilisation

JD Mullan, Professional Manager Pharmacy Services, Acute and Regional Eamon Mullaney, Professional Manager Pharmacy Services, BHSCT Medicines

Procurement & Regional Pharmacy Manufacturing Services

Sharon O'Donnell, Lead Medication Safety Pharmacist

Aideen O'Kane, Encompass Lead Pharmacist

Cathy Woods, Interim Service manager/Senior Nurse, Community Sites

		Action	
1.	Welcome & Apologies:		
	Apologies were received from Mark Cross.		
2.	Minutes of previous meeting and matters arising		
	i. Oxycodone in fractured neck of femur pathway (M Cross)	E McCusker	
	Eimear to follow up with Mark Cross before the next meeting.	Lividdakei	
	ii. Support for New Drugs Committee (E Mullaney)		
	The committee have met and have updated their Terms of Reference. Eamon		
	Mullaney has had a policy approved by D&T concerning zero cost and nominal cost		
	medicines and this should be of help to the committee. The committee have		
	discussed getting some professional help with the increasing numbers of new		
	medicines coming through the committee and have proposed that a 0.1 or 0.2 whole		
	time equivalent post should be tendered for to assist with the committee's running.		
	To be kept on as an action.	E Mullaney	
	iii. Lidocaine patch prescribing (M Cross)		
	Eimear to follow up with Mark Cross before the next meeting.	E McCusker	
	in Louative cotom generic processibing (NA Cross)		
	iv. Levetiracetam generic prescribing (M Cross)	E McCusker	
	Eimear to follow up with Mark Cross before the next meeting.		
	v. Medicines Optimisation Committee strategic plan (E McCusker)		
	Eimear thanked the committee for the comments & included the final version of the		
	plan with the minutes for information. The committee will follow up on the plan with		
	the working group over the next three years.		
	vi. Homecare incidents – summary update (E Mullaney)		
	JD Mullan reported that whilst the Homecare team are working hard, they are very		
	dependent on the Homecare provider and there are concerns around issues with the		
	provider among different areas of the Trust. Pharmacy are to meet with each of the		
	directorates about HomeCare and the Medicines Delivery Service. JD will ask Eamon	ID 84 !!-	
	what the date for completion on these meetings are and report back to Eimear.	JD Mullan	

	,	vii. Pharmacy Computer system (A O'Kane)	
		Aideen O'Kane's meeting with Mark Cross and Philip Toner on this issue was cancelled and is to be rescheduled. Aideen will follow up and arrange a new date.	A O'Kane
	v	iii. Medicines Optimisation Committee Terms of reference (E McCusker)	
		Included for information; updated with comments received.	
3.	Enco	ompass	
	Eim	ear welcomed Aideen O'Kane in her new role as Encompass Lead Pharmacist. Aideen will	
		vide updates at the meetings in future. Karen Devenney reported that no Lead Nurse for ompass has been appointed yet.	
4.	Med	licines Optimisation dashboard/subcommittee updates	
		ear requested that the formal reports from the groups that are sent to her be signed off he Chair of the group.	
	i.	Medicines Risk and Safety Assurance Group (M Cross)	
		Group looking at issues around eTANs. Since the last meeting, Sharon, Louise and some	
		other attended a meeting with the Board about this. There are issues around this in	
		Primary Care where some practices can't or won't use the electronic document transfer.  The GP adviser flags these issues up with the practices when they arise. Another issue	
		the group were looking at was clozapine refusals.	
		Eimear asked why some meetings have been cancelled and Sharon reported that the	
		was no Chair for those meetings. Eimear advised that a Co-Chair be appointed to prevent	
		this happening again. Dr. Cross is seeking nominations for a Co-Chair for the group but has been unsuccessful so far.	
		Nothing to report on the Medication Safety Thermometer, it will be brought to the next meeting.	
	ii.	Medicines Optimisation Efficiency programme	
		The target for the Trust was £3.758 million and £2.022 Million was achieved, so there	
		was a shortfall of around 1.7 million. Any new savings made in this financial year will go first against the shortfall from the previous year. Eamon Mullaney and Clare McMahon	
		have a meeting arranged to look at the targets for 2022/23. Paediatric gastroenterology	
		are moving to biosimilars and there is a 10% investment to support that switch.	
	iii.	Efficiencies/Biosimilars (E Mullaney/C McMahon)	
		The areas that Eamon will be looking at next for the biosimilars is paediatric	
		gastroenterology and also opthamology. They are currently on their third biosimilar switch.	
		Eimear reported that at the QMS presentation to the Executive team, Cathy Jack picked	
		up on the biosimilars and the differences between the Trusts. Eimear explained that it	
		was to do with the size and complexity of Belfast Trust in relation to the other Trusts.  Cathy Jack has asked for a breakdown of biosimilar switches by speciality for the next	
		QMS presentation.	

	iv.	D&T/New Drugs Committee (M Cross)	
		Nothing new to progress outside formal report submitted.	
	v.	Non Medical Prescribing (E McCusker)  AHP – 29 non-medical prescribers, 206 Nurses, 15 optometrists and 56 Pharmacists.  Currently progressing the renewal process, however the Hub has changed to the Loop and Eimear has lost her editing rights so this needs to be rectified. Non-Medical prescribing policy also being updated and it will be brought to D&T in the next month.	
	vi.	Medical gas committee (E Mullaney)  Eamon has devised an eLearning training package to try to solve the issue of poor attendance at the training sessions.	
	vii.	Immunoglobulin sub-committee (JD Mullan)  JD spoke to James Taggart regarding this and he reported that there has been an increase in the amount of immunoglobulins in quarter 4 in comparison to quarter 3. This could be due to a backlog of invoices that have just been passed. There is full accountability of where these have been used and the indications.	
5.	Chri the	near asked JD with regards to the MIG plan. JD reported that the workplan was brought to T and that meetings will take place in the next few weeks. D&T approved this plan.  This Hagan has been in contact with Eimear with regards to the MIG plan and reported that Trust Primary Care Medicines Management will be meeting soon. Mr Hagan has asked they consider the Encompass reports and all the areas where the prescribing is different in the rest of the UK as part of the report.	
6.	Date	te & Time of Next Meeting: Sept 23 <sup>rd</sup> 2022 at 11:00	